Oragenics, Inc. Files 8-K: Material Definitive Agreement
Ticker: OGEN · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1174940
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Oragenics signed a big deal, filing an 8-K on 6/25/24.
AI Summary
On June 25, 2024, Oragenics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. Specific details of the agreement and financial information were not provided in this excerpt.
Why It Matters
This filing indicates a significant new agreement for Oragenics, Inc., which could impact its business operations and financial future.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in this excerpt necessitates a medium risk assessment.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- June 25, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Oragenics, Inc. on June 25, 2024?
The provided excerpt does not specify the details of the material definitive agreement.
What other events are reported in this 8-K filing?
The excerpt mentions 'Other Events' but does not provide specific details.
What financial statements and exhibits are included with this filing?
The excerpt indicates that financial statements and exhibits are filed, but their content is not detailed.
What is Oragenics, Inc.'s principal executive office address?
Oragenics, Inc.'s principal executive offices are located at 1990 Main Street, Suite 750, Sarasota, FL 34236.
What is Oragenics, Inc.'s telephone number?
Oragenics, Inc.'s telephone number is 813-286-7900.
Filing Stats: 907 words · 4 min read · ~3 pages · Grade level 10.5 · Accepted 2024-06-26 16:35:41
Key Financial Figures
- $0.001 — f the Company's common stock, par value $0.001 ("Common Stock"). The offering price pe
- $1.00 — ring price per share of Common Stock is $1.00. The Placement Agent agreed to use it
- $75,000 — le fees of legal counsel, not to exceed $75,000. In addition, the Company agreed to iss
- $1.1 million — pany of approximately are approximately $1.1 million before deducting placement agent fees a
Filing Documents
- form8-k.htm (8-K) — 53KB
- ex1-1.htm (EX-1.1) — 195KB
- ex4-1.htm (EX-4.1) — 129KB
- ex5-1.htm (EX-5.1) — 20KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-2.htm (EX-99.2) — 12KB
- ex99-3.htm (EX-99.3) — 11KB
- ex5-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-24-025281.txt ( ) — 697KB
- ogen-20240625.xsd (EX-101.SCH) — 3KB
- ogen-20240625_lab.xml (EX-101.LAB) — 33KB
- ogen-20240625_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 26 th day of June, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer